CCL2 and breast cancer: Previous studies have suggested that effector T cell-derived IFNγ contributes to high levels of PD-1 expression in the tumor microenvironment (42); CCL2 attracts monocytes, increases the number of tumor-associated macrophages and promotes angiogenesis in breast cancer (43).